Drugs / CGC729
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06394622 | Apr 2024 → Jun 2026 | cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT06182735 | Jul 2023 → Jan 2025 | renal cell carcinoma | Fudan University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-04 | Suzhou Cure Genetics Biosciences Co., Limited. | Results CureGenetics Announces Promising Phase I clinical update for CGC729, an Anti-CD70 CAR-NKT Therapy for Relapsed/Refractory Metastatic Renal Cell Carcinoma curegenetics.com ↗
CureGenetics, a clinical-stage biotechnology company pioneering chimeric antigen receptor natural killer T (CAR-NKT) Cell therapies for solid tumors and immune-mediated diseases, today announced encouraging clinical data from an investigator-initiated Phase I trial of CGC729. |
| 2024-05-20 | Suzhou Cure Genetics Biosciences Co., Limited. | Results Cure Genetics announced the interim data of CAR-NKT product for patients withRCC in an oral presentation at the 27th ASGCT curegenetics.com ↗
This marked the first human trial using CAR-NKT therapy for RCC, demonstrating its good safety profile and anti-tumor activity. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-04 | Suzhou Cure Genetics Biosciences Co., Limited. | CureGenetics Announces Promising Phase I clinical update for CGC729, an Anti-CD70 CAR-NKT Therapy for Relapsed/Refractory Metastatic Renal Cell Carcinoma curegenetics.com ↗ |
| 2024-05-20 | Suzhou Cure Genetics Biosciences Co., Limited. | Cure Genetics announced the interim data of CAR-NKT product for patients withRCC in an oral presentation at the 27th ASGCT curegenetics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGC729 | “This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC729 in the treatment of advanced malignant solid tumors.” NCT06394622 ↗1“During the treatment period of the study, three dose levels of CGC729 will be evaluated.” NCT06182735 ↗ |
| Modality | Cell therapy | “Biological: CD70 CAR-NKT cells.” NCT06394622 ↗ |
| Route | Other | “Followed by infusion of CAR-NKT on day 0.” NCT06394622 ↗ |
| Target | CD70 | “CD70-targeted CAR-NKT Cells Therapy” NCT06394622 ↗ |